The Hidden Burden: Gastrointestinal Involvement in Lysosomal Storage Disorders
Metabolites · 29.05.2025 · 15 (6) · 361
DOI: 10.3390/metabo15060361 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 29.05.2025. Verfasst von Vincenza Gragnaniello und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Inherited Metabolic Diseases, Department of Women's and Children's Health, University Hospital of Padova, 35128 Padova, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lysosomal storage disorders (LSDs) are rare inherited metabolic diseases characterized by defects in lysosomal enzyme function or membrane transport. These defects lead to substrate accumulation and multisystemic manifestations. This review focuses on gastrointestinal (GI) involvement in LSDs, which is a significant but often overlooked aspect of these disorders.
Methods
A comprehensive literature review was conducted to examine the pathophysiology, clinical presentation, diagnosis and management of GI manifestations in several LSDs, including Fabry disease, Gaucher disease, Pompe disease, Niemann–Pick disease type C, mucopolysaccharidoses and Wolman disease.
Results
The pathogenesis of GI involvement in LSDs varies and encompasses substrate accumulation in enterocytes, mesenteric lymphadenopathy, mass effects, smooth muscle dysfunction, vasculopathy, neuropathy, inflammation and alterations to the microbiota. Clinical presentations range from non-specific symptoms, such as abdominal pain, diarrhea and malabsorption, to more severe complications, such as protein-losing enteropathy and inflammatory bowel disease. Diagnosis often requires a high level of suspicion, as GI symptoms may precede the diagnosis of the underlying LSD or be misattributed to more common conditions. Management strategies include disease-specific treatments, such as enzyme replacement therapy or substrate reduction therapy, as well as supportive care and targeted interventions for specific GI complications.
Conclusions
This review highlights the importance of recognizing and properly managing GI manifestations in LSDs to improve patient outcomes and quality of life. It also emphasizes the need for further research to develop more effective treatments for life-threatening GI complications associated with these rare genetic disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Inherited Metabolic Diseases, Department of Women's and Children's Health, University Hospital of Padova, 35128 Padova, Italy.
ORCID-Profile: Alberto B Burlina
Zitieren
APA
Gragnaniello, V., Cazzorla, C., Gueraldi, D., Puma, A., Loro, C., & Burlina, A. B. (2025). The Hidden Burden: Gastrointestinal Involvement in Lysosomal Storage Disorders. Metabolites, 15(6), 361. https://doi.org/10.3390/metabo15060361
Vancouver
Gragnaniello V, Cazzorla C, Gueraldi D, Puma A, Loro C, Burlina AB. The Hidden Burden: Gastrointestinal Involvement in Lysosomal Storage Disorders. Metabolites. 2025;15(6):361. doi:10.3390/metabo15060361
BibTeX
@article{Gragnaniello2025,
author = {Gragnaniello, Vincenza and Cazzorla, Chiara and Gueraldi, Daniela and Puma, Andrea and Loro, Christian and Burlina, Alberto B},
title = {The Hidden Burden: Gastrointestinal Involvement in Lysosomal Storage Disorders},
journal = {Metabolites},
year = {2025},
volume = {15},
number = {6},
pages = {361},
doi = {10.3390/metabo15060361}
}
EUVIMED